Esperion stock falls on higher operating expense forecast

Investing.com — Shares of Esperion (NASDAQ:) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, 2025. In a presentation at the 43rd Annual J.P. Morgan Healthcare Conference held on January 15, 2025, Esperion projected research & development costs to be between $55 million to $65 million and selling, general, and administrative expenses to range from $160 million to $170 million.

The updated financial guidance indicates that the company anticipates operating expenses to total between $215 million and $235 million for the year. This forecast represents a significant increase in the company’s spending, which has prompted today’s decline in stock value as investors react to the potential impact on Esperion’s financial position.

Esperion’s announcement has come as a key factor in today’s trading session, with the higher end of the operating expense range being particularly noteworthy for investors. The increase in projected expenses may raise concerns about the company’s cost management and its effects on profitability in the coming year.

While the company did not provide specific reasons for the expected rise in expenses, research & development and selling, general, and administrative costs are typical areas of investment for pharmaceutical companies like Esperion. These investments are often necessary for the development of new drugs and the expansion of market reach for existing products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.